18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) at diagnosis provided a “very useful predictive tool” for patients with soft tissue sarcoma and bone sarcoma, according to an article in the European Journal of Cancer.1

Investigators performed a systematic review to provide an up-to-date and ground-breaking summary of the prognostic value of 18F-FDG PET. They searched MEDLINE, EMBASE, and Web of Science for studies evaluating pretreatment with 18F-FDG PET for overall survival of patients with soft tissue sarcoma and bone sarcoma. They performed comparative analyses of the pooled hazard ratios of overall survival between patients with high and low maximum standardized uptake value (SUVmax).

Continue Reading

A total of 6 studies comprising 514 patients were included in the meta-analysis. Results revealed that the pooled hazard ratio for overall survival was 1.22 (95% CI, 1.03 – 1.46), which suggested that high SUVmax predicted a significantly shorter overall survival period than low SUVmax (P = .03).

RELATED: Advanced Synovial Sarcomas Respond to Chemo Better Than Other STS Subtypes

Subgroup analyses using patients with soft tissue sarcoma alone revealed that high SUVmax might predict poorer overall survival than low SUVmax (P = .004). The authors noted that only 2 studies were included in this analysis, however, their overall quality by Newcastle-Ottawa scale assessment was adequate.


  1. Kubo T, Furuta T, Johhan MP, Ochi M. Prognostic significance of 18F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis. Euro J Cancer. 2016;58:104-111.